Alvotech
Alvotech (ALVO): 4 pipeline candidates · 2 upcoming catalysts · ~18 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
17.5 months
D/E -6.23 · 0% dilution
Lead: Approved
4 candidates
2 upcoming, next in ~1d
N/A
A transparent, data-derived signal for Alvotechacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.2B
Cash
$172.4M
Quarterly Burn
$50.2M
Runway
17.5 mo
Revenue
$586.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| avt29 | Phase 3 |
| avt32-drl_pb | Phase 1 |
| eylea hd | Phase 3 |
| onsolis | Approved |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$54.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,820,894 | $23.7M |
| millennium management llc | 2,122,596 | $7.3M |
| littlejohn & co llc | 1,318,534 | $4.5M |
| blackrock, inc. | 1,245,195 | $4.3M |
| vanguard fiduciary trust co | 974,228 | $3.4M |
| legal & general group plc | 504,460 | $1.7M |
| geode capital management, llc | 324,199 | $1.1M |
| ubs group ag | 322,157 | $1.1M |
| oaktree capital management lp | 578,058 | $1.0M |
| morgan stanley | 243,277 | $834K |
Showing top 10 of 55 institutional holders of Alvotech. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Alvotech's pipeline?
Alvotech (ALVO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Alvotech's lead drug candidate?
Alvotech's most advanced tracked candidate is avt29 (Phase 3) for Diabetic Macular Edema.
What is Alvotech's next catalyst?
Alvotech's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Multicenter, Randomized, Double-Blind, 2-Treatment Arm Study to Assess Comparative Pharmacokinetic" — expected June 19, 2026.
What is Alvotech's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Alvotech has approximately 17.5 months of cash runway.
What is Alvotech's market capitalization?
Alvotech's market capitalization is approximately $1.2B.
Get the full picture on Alvotech
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.